Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocytic lymphohistiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HPHongwei Peng

Discussion

Loading...

Member takes

Overview

In vitro analysis found NX-5948 improved macrophage polarization and reduced cytokine storm in secondary HLH models, indicating strong therapeutic potential.

Key Points

  • NX-5948 significantly reduced inflammation and improved outcomes in a secondary HLH mouse model, showing promising efficacy.
  • Quantitative assessment revealed that NX-5948 induced macrophage apoptosis at lower concentrations, outperforming comparator drugs like ruxolitinib.
  • Assessment using flow cytometry and Western blot analysis demonstrated effective modulation of the BTK/NF-κB pathway.
  • These findings highlight the potential of BTK degraders to enhance clinical strategies for managing hemophagocytic lymphohistiocytosis.

Cite This Study

Hongwei Peng (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd2fhttps://doi.org/10.1182/blood-2025-187
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BTK Inhibitor Downregulates IL-17 Secretion and Enhances CD20mb Sensitivity to ABC Type Diffuse Large B-cell Lymphoma via CYLD/NF-kB Signaling Pathway2025
  2. 2Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.2025 · 1 citations
  3. 3Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis2025
  4. 4Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial2025 · 6 citations
  5. 5High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma2025